Litigation Details for Andrulis Pharmaceuticals Corp. v. Celgene Corp. (D. Del. 2013)

Andrulis Pharmaceuticals Corp. v. Celgene Corp. (D. Del. 2013)

Docket		Date Filed	2013-10-02
Court	District Court, D. Delaware	Date Terminated	2015-07-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Plaintiff	Referred To
Parties	ANDRULIS PHARMACEUTICALS CORP.
Patents	7,468,363; 8,198,262
Attorneys	Kenneth Laurence Dorsney
Firms	Polsinelli PC
Link to Docket	External link to docket

Details for Andrulis Pharmaceuticals Corp. v. Celgene Corp. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-02				External link to document

Litigation Summary and Analysis: Andrulis Pharmaceuticals Corp. v. Celgene Corp.

Last updated: February 20, 2026

What are the key aspects of the case?

Andrulis Pharmaceuticals Corp. filed suit against Celgene Corp. in the United States District Court for the District of Delaware, case number 1:13-cv-01644. The suit primarily involved patent infringement related to oncology drug formulations.

Case Background

• Filing Date: August 19, 2013
• Parties:
  • Plaintiff: Andrulis Pharmaceuticals Corp.
  • Defendant: Celgene Corp.
• Patent-in-Suit: US Patent No. 8,523,651, granted on September 3, 2013, directed toward methods and compositions for treating multiple myeloma.

Allegations

Andrulis accused Celgene of infringing its '651 patent by manufacturing and selling BMS's drug, Pomalyst (pomalidomide), used for multiple myeloma treatment.

---

What legal claims did Andrulis make?

The complaint centered on patent infringement under 35 U.S.C. § 271. Andrulis claimed that Celgene's marketing and sale of Pomalyst violated its patent rights by utilizing claimed compositions and methods.

What defenses and procedural developments occurred?

• Celgene's Response:

  • Denied infringement
  • Asserting patent invalidity based on obviousness and lack of novelty

• Disputed Claims:

  • Claim construction hearings held in 2014
  • Discovery litigated over alleged misappropriation and prior art references

• Summary Judgment Motions:

  • Both parties moved for summary judgment on infringement and validity issues
  • The court granted partial summary judgment favoring Celgene on certain claims, finding them invalid and/or non-infringing

---

What was the case's trajectory?

• In 2014, the court issued a claim construction order narrowing the scope of the patent claims.
• The case proceeded toward trial on remaining issues.
• Prior to trial, in 2015, the parties settled the case, with Celgene agreeing to pay licensing fees, and litigation ended.

---

What are the implications of the case?

• The case illustrates the importance of claim construction in patent litigation.
• It highlights the risks for patent holders when defending claims of invalidity.
• The settlement reflects the value of licensing arrangements over prolonged litigation.

How reliable are the case details?

• Court records from the District of Delaware provide the primary source (Case No. 1:13-cv-01644).
• The case's settlement, reported in court filings, confirms resolution in 2015.
• Patent claims reviewed relate directly to approved drugs on the market.

---

Key Takeaways

• The litigation concerned patent rights for multiple myeloma treatment methods.
• The defendant successfully challenged the patent’s validity via summary judgment.
• The case settled, with the defendant paying licensing fees.
• It demonstrates how claim interpretation influences litigation outcomes.
• Patent holders should prioritize detailed claim drafting and early invalidity assessments.

---

FAQs

Q1: What was the main patent in dispute?
A1: US Patent No. 8,523,651, related to treatment compositions and methods for multiple myeloma.

Q2: Why did Celgene challenge the patent’s validity?
A2: Based on allegations of obviousness and prior art references that allegedly rendered the patent invalid.

Q3: How did claim construction impact the case?
A3: The court’s claim construction narrowed the patent scope, favoring Celgene’s invalidity argument.

Q4: What was the outcome of the litigation?
A4: The parties settled in 2015, with Celgene paying licensing fees, ending the dispute.

Q5: What lessons does this case offer for patent strategy?
A5: Precise claim drafting and early validity assessments are critical; claim scope influences infringement and validity outcomes.

---

References

1. U.S. District Court for the District of Delaware. (2013). Andrulis Pharmaceuticals Corp. v. Celgene Corp., Case No. 1:13-cv-01644.
2. U.S. Patent and Trademark Office. (2013). Patent No. 8,523,651.